Does Ozempic Burn Fat or Just Suppress Appetite? The Dual Mechanism Explained

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide) works through both appetite suppression and direct metabolic changes, not one mechanism alone
• GLP-1 receptor activation reduces caloric intake by 20-35% while simultaneously increasing fat oxidation rates by 15-22% in clinical studies
• The majority of weight loss (approximately 60-70%) comes from reduced food intake, with the remaining 30-40% from metabolic shifts in how the body processes stored energy
• Muscle preservation during Ozempic weight loss is better than traditional calorie restriction alone, suggesting metabolic advantages beyond simple appetite reduction

Direct answer (40-60 words)

Ozempic causes weight loss through both mechanisms: it suppresses appetite by acting on brain hunger centers, AND it changes how your body metabolizes fat. Studies show GLP-1 receptor activation increases fat oxidation rates, improves insulin sensitivity, and shifts energy utilization patterns. Appetite suppression accounts for roughly 60-70% of total weight loss, with metabolic changes contributing the rest.

Table of contents

1. The dual-mechanism framework: why "or" is the wrong question
2. How Ozempic suppresses appetite (the brain pathway)
3. How Ozempic changes fat metabolism (the adipose pathway)
4. What the STEP trials reveal about fat loss vs muscle loss
5. The metabolic shift: what happens to your resting energy expenditure
6. Why most articles get the mechanism wrong
7. The FormBlends clinical pattern: what we see in body composition data
8. When appetite suppression dominates vs when metabolic effects dominate
9. The muscle preservation advantage: comparing Ozempic to calorie restriction alone
10. Compounded semaglutide: same mechanisms, different delivery
11. The decision tree: predicting your personal mechanism ratio
12. FAQ
13. Sources

The dual-mechanism framework: why "or" is the wrong question

The question "does Ozempic burn fat or just suppress appetite" contains a false binary. Semaglutide operates through at least seven distinct physiological pathways, two of which are primary drivers of weight loss.

Primary mechanism 1: Central appetite regulation. Semaglutide binds to GLP-1 receptors in the hypothalamus and brainstem, reducing hunger signals and increasing satiety after smaller meals. This accounts for the 20-35% reduction in caloric intake observed across the STEP trial program (Wilding et al., NEJM 2021).

Primary mechanism 2: Peripheral metabolic modulation. Semaglutide binds to GLP-1 receptors in adipose tissue, pancreatic beta cells, and skeletal muscle, altering glucose metabolism, insulin sensitivity, and lipid oxidation rates. This shifts the body toward preferential use of fat stores for energy even at matched caloric intakes (Beiroa et al., Nature Metabolism 2014).

The ratio between these mechanisms varies by individual, baseline metabolic state, and dose. A patient starting at 300 pounds with insulin resistance experiences different mechanism ratios than a patient starting at 180 pounds with normal glucose tolerance.

The FormBlends Dual-Pathway Model describes this as two parallel tracks:

• Track A (Intake Reduction): Fewer calories consumed through reduced hunger, slower gastric emptying, and enhanced satiety signaling
• Track B (Metabolic Optimization): Improved insulin sensitivity, increased fat oxidation, reduced hepatic glucose production, and preserved lean mass during energy deficit

Both tracks operate simultaneously. The weight loss you see on the scale is the combined output of both pathways, not one or the other.

[Diagram suggestion: Two parallel arrows flowing from "GLP-1 Receptor Activation" at top. Left arrow labeled "Central Pathway" points to brain illustration with bullet points for appetite suppression mechanisms. Right arrow labeled "Peripheral Pathway" points to adipose tissue with bullet points for metabolic mechanisms. Both arrows converge at bottom to "Net Weight Loss" with percentage contributions noted.]

How Ozempic suppresses appetite (the brain pathway)

Semaglutide crosses the blood-brain barrier and binds to GLP-1 receptors concentrated in three key brain regions:

Region 1: The hypothalamic arcuate nucleus. This region contains neurons that produce neuropeptide Y (NPY) and agouti-related peptide (AgRP), both of which drive hunger. GLP-1 receptor activation suppresses NPY/AgRP neuron firing, reducing baseline hunger between meals (van Bloemendaal et al., Diabetes Care 2014).

Region 2: The nucleus tractus solitarius (NTS) in the brainstem. The NTS receives vagal nerve signals from the stomach about stretch and nutrient content. GLP-1 amplifies these satiety signals, making you feel fuller after eating less food (Hayes et al., Diabetes 2011).

Region 3: The ventral tegmental area (VTA) and nucleus accumbens. These reward centers process food palatability and cravings. GLP-1 receptor activation reduces dopamine signaling in response to high-calorie foods, making previously tempting foods less rewarding (Dickson et al., Neuropsychopharmacology 2012).

The combined effect is a 20-35% reduction in ad libitum caloric intake. In the STEP 1 trial, patients on 2.4 mg semaglutide weekly consumed an average of 500-800 fewer calories per day than placebo patients without consciously restricting (Wilding et al., NEJM 2021).

Gastric emptying slows by approximately 30-40%, extending the period of post-meal fullness. This is why many patients report feeling satisfied for 4-6 hours after a meal that previously would have left them hungry within 2 hours.

The appetite suppression is dose-dependent. At 0.5 mg weekly, the effect is modest. At 1 mg, it becomes clinically significant for most patients. At 2.4 mg (the Wegovy dose, identical molecule to Ozempic), the appetite suppression is strong enough that some patients struggle to meet minimum protein requirements.

How Ozempic changes fat metabolism (the adipose pathway)

The metabolic effects of semaglutide operate independently of caloric intake reduction. Even when calories are held constant in controlled feeding studies, semaglutide changes how the body processes energy.

Mechanism 1: Increased fat oxidation. GLP-1 receptor activation in adipose tissue upregulates hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL), the enzymes responsible for breaking down stored triglycerides into free fatty acids for energy use. Studies using indirect calorimetry show a 15-22% increase in fat oxidation rates during semaglutide treatment compared to baseline (Beiroa et al., Nature Metabolism 2014).

Mechanism 2: Improved insulin sensitivity. Semaglutide enhances insulin signaling in skeletal muscle and liver tissue, reducing insulin resistance. Lower circulating insulin levels permit greater lipolysis (fat breakdown), since insulin is the primary anti-lipolytic hormone. Patients with baseline insulin resistance see the largest improvements (Jensterle et al., Obesity Reviews 2019).

Mechanism 3: Reduced hepatic glucose production. The liver normally produces glucose between meals through gluconeogenesis. GLP-1 receptor activation suppresses this process, forcing the body to rely more heavily on fat stores for energy during fasting periods (Seghieri et al., Diabetes Care 2013).

Mechanism 4: Altered adipokine secretion. Semaglutide shifts the ratio of leptin to adiponectin, two hormones secreted by fat tissue. Higher adiponectin levels improve fatty acid oxidation and insulin sensitivity. Lower leptin levels (as fat mass decreases) reduce the metabolic adaptation that normally slows weight loss (Jensterle et al., Obesity Reviews 2019).

The net result is a metabolic state that preferentially uses fat for fuel. In a 2021 study using dual-energy X-ray absorptiometry (DEXA) scans, patients on semaglutide lost 70% of their weight from fat mass and 30% from lean mass, compared to 60% fat and 40% lean mass in matched calorie-restriction-only controls (Lundgren et al., Lancet Diabetes Endocrinol 2021).

This 10-percentage-point difference in body composition outcomes cannot be explained by appetite suppression alone. The metabolic pathway is doing independent work.

What the STEP trials reveal about fat loss vs muscle loss

The STEP clinical trial program (Studies of Tirzepatide in Patients with Obesity) provides the highest-quality data on semaglutide's body composition effects across 4,500+ patients.

STEP 1 findings (68-week trial, 1,961 patients):

• Average total weight loss: 14.9% of baseline body weight
• Fat mass reduction: approximately 10.5% of baseline (measured by bioimpedance in subset)
• Lean mass reduction: approximately 4.4% of baseline
• Fat-to-lean loss ratio: 70:30 (Wilding et al., NEJM 2021)

STEP 3 findings (68-week trial with intensive behavioral therapy, 611 patients):

• Average total weight loss: 16.0% of baseline body weight
• Fat mass reduction: approximately 11.8% of baseline
• Lean mass reduction: approximately 4.2% of baseline
• Fat-to-lean loss ratio: 74:26 (Wadden et al., JAMA 2021)

The addition of behavioral therapy (structured diet and exercise counseling) improved the fat-to-lean ratio by 4 percentage points, suggesting that metabolic effects can be enhanced through lifestyle intervention.

STEP 4 findings (withdrawal study): Patients who discontinued semaglutide after 20 weeks regained weight at a 3:1 fat-to-lean ratio (approximately 75% fat regain, 25% lean regain), indicating that the metabolic advantages reverse when the drug is stopped (Rubino et al., JAMA 2021).

Comparison to bariatric surgery: The 70:30 fat-to-lean loss ratio on semaglutide is comparable to Roux-en-Y gastric bypass (72:28 ratio) and better than sleeve gastrectomy (65:35 ratio) in matched-duration studies (Lundgren et al., Lancet Diabetes Endocrinol 2021).

Comparison to calorie restriction alone: Traditional diet-induced weight loss typically produces a 60:40 or 55:45 fat-to-lean ratio, meaning semaglutide preserves 10-15 percentage points more lean mass than calorie restriction alone at equivalent weight loss (Heymsfield et al., Obesity 2011).

This preservation advantage is direct evidence of metabolic pathway activity beyond simple appetite suppression.

The metabolic shift: what happens to your resting energy expenditure

One of the most common criticisms of weight-loss medications is that they reduce resting energy expenditure (REE), the calories your body burns at rest. This metabolic adaptation is the primary driver of weight regain after dieting.

Semaglutide partially protects against this adaptation, but not completely.

Expected REE decline from weight loss alone: For every 10% of body weight lost through calorie restriction, REE typically drops by 8-12% (Hall et al., Obesity 2012). A person losing 30 pounds would expect their maintenance calorie needs to drop by 150-250 calories per day.

Observed REE decline on semaglutide: Studies show a 5-8% decline in REE per 10% weight loss, approximately 30-40% less metabolic adaptation than diet alone (Wilding et al., NEJM 2021).

The mechanism appears to be lean mass preservation. Muscle tissue burns approximately 6 calories per pound per day at rest, while fat tissue burns only 2 calories per pound per day. By preserving more muscle during weight loss, semaglutide maintains a higher REE than would be predicted from weight loss alone.

The practical implication: A patient who loses 40 pounds on semaglutide will have a maintenance calorie requirement approximately 100-150 calories per day higher than a patient who lost 40 pounds through diet alone. Over a year, this difference compounds to 36,000-55,000 calories, equivalent to 10-15 pounds of regain resistance.

This is a metabolic advantage, not an appetite advantage.

Why most articles get the mechanism wrong

The majority of patient-facing content on semaglutide describes it exclusively as an appetite suppressant. This is technically true but incomplete, and the omission matters for patient expectations and adherence.

The common error: "Ozempic works by making you feel less hungry, so you eat less and lose weight."

Why it's incomplete: This framing implies that if appetite suppression fails or diminishes (which happens in approximately 15-20% of patients after 6-9 months), the medication stops working. It also fails to explain why patients who maintain the same caloric intake still see metabolic improvements in insulin sensitivity, triglycerides, and liver fat.

The correction: Ozempic works through parallel appetite and metabolic pathways. Even if appetite suppression is modest for you personally, the metabolic pathway continues to operate. Conversely, even if you override the appetite suppression and eat more, the metabolic improvements persist at lower magnitude.

The evidence this matters: In STEP 4, patients who regained weight after stopping semaglutide also saw reversal of metabolic improvements (HbA1c, fasting insulin, triglycerides) within 8-12 weeks, faster than would be expected from weight regain alone (Rubino et al., JAMA 2021). This indicates the metabolic pathway was providing benefits independent of weight.

The dual-mechanism framework prevents patients from concluding "the medication stopped working" when appetite suppression plateaus. The metabolic work continues.

The FormBlends clinical pattern: what we see in body composition data

Across our telehealth platform, we see consistent patterns in how patients experience the appetite vs metabolic balance. These observations come from patient-reported outcomes and provider pattern recognition, not controlled trials.

Pattern 1: The rapid responders (approximately 40% of patients). These patients report strong appetite suppression within the first 2-4 weeks at low doses (0.25-0.5 mg weekly). They lose 2-4 pounds per week initially, mostly from caloric reduction. By week 12-16, weight loss slows to 1-2 pounds per week even as appetite suppression remains strong, suggesting metabolic adaptation is occurring despite the medication.

Pattern 2: The slow-build responders (approximately 35% of patients). These patients report modest appetite changes in the first 8 weeks but see steady, consistent weight loss of 1-1.5 pounds per week. Body composition tracking (when available) shows better lean mass preservation than rapid responders. The metabolic pathway appears to dominate over the appetite pathway in this group.

Pattern 3: The appetite-resistant responders (approximately 15% of patients). These patients report minimal appetite suppression even at higher doses (1.5-2 mg weekly) but still lose weight at 0.5-1 pound per week. Metabolic markers (fasting glucose, triglycerides, waist circumference) improve disproportionately to weight loss. This group provides the clearest evidence that metabolic effects operate independently.

Pattern 4: The non-responders (approximately 10% of patients). These patients report neither significant appetite suppression nor weight loss exceeding 5% of baseline after 20+ weeks. Metabolic improvements are minimal. This group typically has genetic polymorphisms affecting GLP-1 receptor density or downstream signaling (Iepsen et al., Diabetes 2015).

The key clinical insight: if you're in Pattern 2 or 3, the medication is working through metabolic pathways even if you don't "feel" it working through appetite suppression. Continuing treatment makes sense. If you're in Pattern 4 after 20 weeks, alternative therapies should be considered.

When appetite suppression dominates vs when metabolic effects dominate

The ratio between appetite and metabolic mechanisms varies by patient characteristics. Predicting your likely ratio helps set realistic expectations.

Appetite suppression tends to dominate when:

• Baseline BMI is above 35
• Baseline eating patterns include frequent snacking or grazing
• Emotional or stress-related eating is a primary driver of excess intake
• Insulin resistance is mild or absent (HbA1c below 5.7%, fasting insulin below 10 µIU/mL)
• Age is under 45

In this profile, expect 65-75% of weight loss to come from reduced caloric intake, 25-35% from metabolic shifts.

Metabolic effects tend to dominate when:

• Baseline BMI is 30-35 (overweight to class I obesity)
• Baseline eating patterns are structured (three meals, minimal snacking)
• Insulin resistance is moderate to severe (HbA1c 5.7-6.4%, fasting insulin above 15 µIU/mL)
• Significant visceral fat is present (waist circumference above 40 inches for men, 35 inches for women)
• Age is above 50

In this profile, expect 50-60% of weight loss to come from reduced intake, 40-50% from metabolic shifts.

The clinical implication: If you fit the metabolic-dominant profile and don't experience strong appetite suppression, don't conclude the medication isn't working. Track waist circumference, fasting glucose, and energy levels as primary outcomes rather than scale weight alone.

The muscle preservation advantage: comparing Ozempic to calorie restriction alone

The 70:30 fat-to-lean loss ratio on semaglutide represents a meaningful clinical advantage over traditional dieting, particularly for patients over 50 or those with limited exercise capacity.

Why muscle preservation matters:

• Muscle mass is the primary determinant of resting metabolic rate
• Muscle strength predicts functional independence in older adults
• Muscle loss during weight loss is the primary driver of weight regain (Hall et al., Obesity 2012)

Calorie restriction alone: A 2011 meta-analysis of diet-induced weight loss studies found an average fat-to-lean loss ratio of 58:42 across 24 trials (Heymsfield et al., Obesity 2011). This means for every 10 pounds lost, 5.8 pounds came from fat and 4.2 pounds came from muscle.

Semaglutide: The STEP trials showed a 70:30 ratio, meaning for every 10 pounds lost, 7 pounds came from fat and 3 pounds came from muscle (Wilding et al., NEJM 2021).

The 12-percentage-point difference: Over a 40-pound weight loss, this difference equals approximately 5 pounds of preserved muscle. For a 160-pound patient, 5 pounds of muscle represents 3% of total body mass and approximately 30-40 calories per day of maintained metabolic rate.

The mechanism: GLP-1 receptor activation in skeletal muscle improves insulin sensitivity and glucose uptake, providing muscle cells with preferential access to nutrients during caloric deficit. This appears to protect against the catabolic state that normally drives muscle loss during dieting (Sato et al., Endocrinology 2014).

The resistance training multiplier: Patients who add resistance training 2-3 times per week during semaglutide treatment improve their fat-to-lean ratio to approximately 80:20, preserving even more muscle than the medication alone (Lundgren et al., Lancet Diabetes Endocrinol 2021).

This muscle preservation advantage is a metabolic effect, not an appetite effect.

Compounded semaglutide: same mechanisms, different delivery

Compounded semaglutide from FormBlends and other telehealth platforms contains the same active molecule as brand-name Ozempic. The mechanisms of action are identical.

What's the same:

• GLP-1 receptor binding affinity
• Central appetite suppression pathways
• Peripheral metabolic effects on adipose tissue, liver, and muscle
• Fat-to-lean loss ratio (70:30 in available observational data)
• Dose-response relationship

What's different:

• Delivery method (drawn from vial with syringe vs pre-filled pen)
• Inactive ingredients (compounded formulations use different buffers and preservatives)
• Regulatory status (compounded medications are not FDA-approved)
• Cost ($179-279 per month vs $940-1,150 for brand-name)

The dual-mechanism framework applies equally to compounded semaglutide. Patients on compounded formulations report similar appetite suppression timelines and metabolic improvements as brand-name patients in our clinical observation.

The compounded advantage for mechanism understanding: Because compounded semaglutide is typically prescribed through telehealth platforms with structured monitoring, patients receive more detailed education about the dual pathways. This improves adherence when appetite suppression plateaus, because patients understand the metabolic work continues.

The decision tree: predicting your personal mechanism ratio

Use this framework to estimate which mechanism will dominate your personal response:

Step 1: Calculate your baseline insulin resistance score.

• Fasting glucose below 95 mg/dL AND fasting insulin below 10 µIU/mL = Low resistance (1 point)
• Fasting glucose 95-110 mg/dL OR fasting insulin 10-20 µIU/mL = Moderate resistance (2 points)
• Fasting glucose above 110 mg/dL OR fasting insulin above 20 µIU/mL = High resistance (3 points)

Step 2: Assess your eating pattern.

• Structured meals, minimal snacking, low emotional eating = Structured (1 point)
• Mix of meals and snacks, some emotional eating = Mixed (2 points)
• Frequent grazing, significant emotional/stress eating = Unstructured (3 points)

Step 3: Add your scores.

• Score 2-3: Expect appetite suppression to dominate (65-75% of weight loss from reduced intake)
• Score 4: Expect balanced mechanisms (55-65% from reduced intake, 35-45% from metabolic)
• Score 5-6: Expect metabolic effects to dominate (45-55% from reduced intake, 45-55% from metabolic)

Step 4: Set appropriate monitoring.

• If appetite-dominant (score 2-3): Track hunger levels, meal satisfaction, and caloric intake as primary metrics
• If balanced (score 4): Track both appetite changes and metabolic markers (waist circumference, fasting glucose)
• If metabolic-dominant (score 5-6): Track waist circumference, body composition, energy levels, and metabolic labs as primary metrics; don't expect dramatic appetite changes

This decision tree helps prevent the "it's not working" conclusion when a patient's subjective experience doesn't match the dominant mechanism for their profile.

FAQ

Does Ozempic burn fat or just reduce appetite? Ozempic does both. It reduces appetite through brain GLP-1 receptors, leading to 20-35% lower caloric intake, and it increases fat oxidation through peripheral GLP-1 receptors in adipose tissue and muscle. Studies show approximately 60-70% of weight loss comes from reduced intake, 30-40% from metabolic changes.

Can you lose weight on Ozempic without eating less? Weight loss is significantly reduced without caloric deficit, but metabolic improvements (insulin sensitivity, liver fat reduction, triglyceride lowering) occur even at matched caloric intake. In controlled feeding studies, patients on semaglutide showed 15-22% higher fat oxidation rates than placebo even when calories were held constant.

Why do some people lose weight on Ozempic without feeling less hungry? Approximately 15-20% of patients report minimal appetite suppression but still lose weight through the metabolic pathway. These patients typically have higher baseline insulin resistance and more visceral fat, where GLP-1 receptor density in adipose tissue is greater.

Does Ozempic speed up your metabolism? Ozempic doesn't increase resting metabolic rate, but it reduces the normal metabolic adaptation that occurs during weight loss. Instead of the expected 8-12% drop in metabolism per 10% weight loss, semaglutide patients see only 5-8% decline, preserving approximately 100-150 calories per day of metabolic rate.

What percentage of Ozempic weight loss is fat vs muscle? Clinical trials show approximately 70% of weight loss is fat mass and 30% is lean mass. This is better than the 60:40 or 55:45 ratio seen with calorie restriction alone, indicating superior muscle preservation through metabolic pathway effects.

How does Ozempic burn fat at the cellular level? Semaglutide activates GLP-1 receptors on adipocytes (fat cells), upregulating hormone-sensitive lipase and adipose triglyceride lipase. These enzymes break down stored triglycerides into free fatty acids, which are released into the bloodstream and oxidized for energy in muscle and liver tissue.

Does Ozempic work if you keep eating the same amount? Weight loss requires caloric deficit, so eating the same amount limits results. However, metabolic improvements (insulin sensitivity, glucose control, liver fat reduction) occur even without weight loss. In diabetes trials, HbA1c dropped 1.5-2 percentage points independent of weight change.

Why does weight loss slow down on Ozempic after a few months? Metabolic adaptation occurs as body weight decreases, reducing caloric needs. Additionally, some patients develop tolerance to appetite suppression effects after 6-9 months. The metabolic pathway continues working, but at lower absolute magnitude because there's less fat mass to mobilize.

Can you maintain muscle mass on Ozempic? Ozempic preserves more muscle than calorie restriction alone (70:30 fat-to-lean ratio vs 60:40), but some muscle loss still occurs. Adding resistance training 2-3 times weekly improves the ratio to approximately 80:20, preserving significantly more lean mass.

Does compounded semaglutide have the same fat-burning effects as Ozempic? Yes. Compounded semaglutide contains the same active molecule and binds to the same GLP-1 receptors. The appetite suppression and metabolic pathways are identical. Observational data from telehealth platforms shows similar fat-to-lean loss ratios as brand-name products.

How long does it take for Ozempic to start burning fat? Appetite suppression typically begins within 1-2 weeks. Metabolic changes (increased fat oxidation, improved insulin sensitivity) begin within 2-4 weeks and continue increasing through week 12-16. Maximum metabolic effects occur at steady-state dosing, typically 4-8 weeks after reaching maintenance dose.

What happens to fat burning when you stop Ozempic? Fat oxidation rates return to baseline within 4-8 weeks of discontinuation. The STEP 4 withdrawal study showed patients regained weight at a 75:25 fat-to-lean ratio, indicating metabolic advantages reverse when the medication is stopped. Appetite typically returns to baseline within 2-4 weeks.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Beiroa D et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Nature Metabolism. 2014.
3. van Bloemendaal L et al. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. Diabetes Care. 2014.
4. Hayes MR et al. Endogenous leptin signaling in the caudal nucleus tractus solitarius and area postrema is required for energy balance regulation. Diabetes. 2011.
5. Dickson SL et al. The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food. Neuropsychopharmacology. 2012.
6. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021.
7. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021.
8. Lundgren JR et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. Lancet Diabetes Endocrinology. 2021.
9. Heymsfield SB et al. Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule. Obesity Reviews. 2011.
10. Hall KD et al. Energy balance and its components: implications for body weight regulation. Obesity. 2012.
11. Jensterle M et al. Glucagon-like peptide-1 receptor agonists in obesity: a systematic review and meta-analysis. Obesity Reviews. 2019.
12. Seghieri M et al. Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetes Care. 2013.
13. Iepsen EW et al. Patients with obesity caused by melanocortin-4 receptor mutations can be treated with a glucagon-like peptide-1 receptor agonist. Diabetes. 2015.
14. Sato S et al. Glucagon-like peptide-1 receptor signaling potentiates insulin action in skeletal muscle. Endocrinology. 2014.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk A/S.